查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2024557

黃斑部病變治療市場報告：按類型、階段、給藥途徑、最終用戶和地區分類（2026-2034 年）

Macular Degeneration Treatment Market Report by Type, Stage of Disease, Route of Administration, End User, and Region 2026-2034
出版日期: | 出版商: IMARC | 英文 142 Pages | 商品交期: 2-3個工作天內

價格

2025年，全球黃斑部病變治療市場規模達104億美元。展望未來，IMARC Group預測，到2034年，該市場規模將達到162億美元，2026年至2034年的複合年成長率為4.87%。推動該市場成長的主要因素包括：老齡化黃斑部病變病變在一般人群中的盛行率不斷上升、久坐生活方式的蔓延、智慧設備的快速普及以及醫療基礎設施的顯著改善，尤其是在開發中國家。

黃斑部病變治療市場的發展趨勢：

研發活動活性化

目前，大量的研發工作集中在開發針對黃斑部病變特定生化路徑的藥物，例如抑制異常血管生成的抗VEGF療法。這些藥物不僅能改善視力，還能透過延長治療間隔來提高患者的便利性和依從性。此外，緩釋藥物遞送系統和基因療法等技術進步也展現出巨大的潛力，有望成為長期管理和潛在解決方案。學術機構、製藥公司和生技公司之間的合作，為突破性進展創造了沃土，從而提振了老齡化黃斑部病變治療市場的前景。

視網膜疾病負擔加重

視網膜疾病盛行率的上升正在推動市場擴張。例如，根據2020年8月發表在《英國眼科雜誌》上的一篇研究論文，老齡化黃斑部病變黃斑部病變（老齡化 ）是歐洲視力障礙和失明的主要原因之一。 AMD影響歐洲約6,700萬人，隨著人口老化，預計到2050年，這一數字將成長15%。數據顯示，視網膜疾病患者人數的增加與市場成長密切相關。因此，在預測期內，這些疾病盛行率的上升是老齡化黃斑部病變治療市場的主要推動要素。

老年人口增加

全球人口老化將是預測期內全球市場的主要促進因素。視網膜疾病的盛行率老齡化增加而增加。老齡化黃斑部病變（AMD）是已開發國家最常見的致盲原因，尤其是在60歲及以上。根據世界衛生組織（WHO）統計，2019年全球60歲以上人口數已達10億人。預計這將提振市場前景，並增加老齡化黃斑部病變治療市場的收入。

目錄

第1章：序言

第2章：調查方法

  • 調查目的
  • 相關利益者
  • 數據來源
    • 主要訊息
    • 次要訊息
  • 市場估值
    • 自下而上的方法
    • 自上而下的方法
  • 預測方法

第3章執行摘要

第4章：引言

第5章：全球黃斑部病變治療市場

  • 市場概覽
  • 市場表現
  • 新冠疫情的影響
  • 市場預測

第6章 市場區隔：依類型

  • 老齡化黃斑部病變）
  • 濕性老齡化黃斑部病變

第7章 市場區隔：依疾病階段分類

  • 初期
  • 過渡時期
  • 晚期

第8章 市場區隔：依給藥途徑

  • 靜脈注射
  • 玻璃體內注射途徑

第9章 市場區隔：依最終用戶分類

  • 醫院
  • 門診手術中心
  • 其他

第10章 市場區隔：依地區分類

  • 北美洲
    • 美國
    • 加拿大
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 其他
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 俄羅斯
    • 其他
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他
  • 中東和非洲

第11章 SWOT 分析

第12章：價值鏈分析

第13章：波特五力分析

第14章：價格分析

第15章 競爭格局

  • 市場結構
  • 大公司
  • 主要公司簡介
    • Alcon Inc.
    • Apellis Pharmaceuticals, Inc.
    • Astellas Pharma US, Inc.
    • Bausch+Lomb
    • Bayer Consumer Care AG
    • F. Hoffmann-La Roche Ltd
    • Novartis Pharmaceuticals Corporation
    • Ocular Therapeutix, Inc.
    • Regeneron Pharmaceuticals Inc.
    • Regenxbio Inc.
    • Samsung Bioepis
Product Code: SR112026A5118

The global macular degeneration treatment market size reached USD 10.4 Billion in 2025. Looking forward, IMARC Group expects the market to reach USD 16.2 Billion by 2034, exhibiting a growth rate (CAGR) of 4.87% during 2026-2034. The market is majorly driven by the increasing incidences of age-related macular degeneration and obesity among the masses, growing prevalence of sedentary lifestyles, rapid utilization of smart devices, and significant improvements in the healthcare infrastructure, particularly in developing economies.

MACULAR DEGENERATION TREATMENT MARKET ANALYSIS:

  • Major Market Drivers: The increasing prevalence of macular degeneration, especially among the aging population, is a primary market driver. Advances in diagnostic techniques and treatment modalities are also contributing significantly. Rising awareness and early diagnosis initiatives further fuel the market expansion.
  • Key Market Trends: There is a notable shift towards biologics and gene therapy in the treatment of macular degeneration. Minimally invasive procedures and innovative drug delivery systems are gaining traction. Personalized medicine and tailored treatment approaches are becoming increasingly prevalent. This, in turn, is creating a positive macular degeneration treatment market overview.
  • Geographical Trends: North America leads the market due to high healthcare spending and advanced medical infrastructure. Europe also shows substantial growth owing to increased research funding and an aging population. Asia-Pacific is further emerging as a lucrative market due to rising healthcare investments and a growing patient pool.
  • Competitive Landscape: Some of the key market players include Alcon Inc., Apellis Pharmaceuticals, Inc., Astellas Pharma US, Inc., Bausch + Lomb, Bayer Consumer Care AG, F. Hoffmann-La Roche Ltd, Novartis Pharmaceuticals Corporation, Ocular Therapeutix, Inc., Regeneron Pharmaceuticals Inc., Regenxbio Inc. and Samsung Bioepis.
  • Challenges and Opportunities: High treatment costs and limited access to advanced therapies pose significant challenges in the market. However, ongoing research and development present opportunities for novel treatments. Expansion into emerging markets and technological advancements in treatment methods offer potential for future growth.

MACULAR DEGENERATION TREATMENT MARKET TRENDS:

Increasing research and development (R&D) activities

Extensive R&D efforts are being focused on creating medications that target specific biochemical pathways involved in macular degeneration, such as anti-VEGF therapies that prevent aberrant blood vessel formation. These medications not only improve visual outcomes, but they also increase treatment intervals, which improves patient convenience and compliance. Furthermore, technical advancements like as sustained-release drug delivery systems and gene therapy provide great promise for long-term management and potential solutions. Collaboration among academics, pharmaceutical corporations, and biotech enterprises creates a fertile ground for breakthroughs, thereby bolstering the macular degeneration treatment market outlook.

Growing burden of retinal disorders

The rising prevalence of retinal illnesses is contributing to the market expansion. For example, according to a research article published in the British Journal of Ophthalmology in August 2020, age-related macular degeneration (AMD) is the leading cause of vision impairment and blindness in Europe. Age-related macular degeneration (AMD) affects around 67 million people in Europe, and this figure is anticipated to rise by 15% by 2050 as the population ages. According to data, the growing number of people suffering from retinal problems correlates closely with the market growth. Thus, the rising prevalence of such conditions is driving the market during the macular degeneration treatment market forecast period.

Rising geriatric population

The growing geriatric population around the world is likely to drive the global market over the forecast period. The prevalence of retinal diseases rises with age. AMD is the most common cause of blindness in developed countries, especially among individuals over the age of sixty. According to the World Health Organization (WHO), in 2019, the number of people aged 60 years and older was 1 billion. This is expected to create a positive outlook for the market and increase the macular degeneration treatment market revenue.

MACULAR DEGENERATION TREATMENT MARKET SEGMENTATION:

Breakup by Type:

  • Dry Age-related Macular Degeneration
  • Wet Age-related Macular Degeneration

Wet age-related macular degeneration dominates the market

The global macular degeneration treatment market report shows that wet age-related macular degeneration category dominated the global market. Wet AMD is treated with intravitreal injections (IVT), and an estimated 22.3 million operations were performed worldwide in 2017. Approximately 75% of anti-VEGF injections were administered to treat wet AMD. The effectiveness of these treatments, combined with advances in diagnostic technologies, continues to enhance access and therapeutic outcomes for patients suffering from wet AMD. The high prevalence of the condition, branded drugs, more awareness, and an increase in the number of therapies for wet AMD are all contributing to the segment's dominance in the macular degeneration treatment market share.

Breakup by Stage of Disease:

  • Early Stage
  • Intermediate Stage
  • Late Stage

Late stage holds the largest share in the market

The late stage of macular degeneration has a substantial impact on the market. As the disorder progresses, individuals experience severe vision impairment. The necessity to treat this illness fuels research and interest in these treatments. Pharmaceutical corporations are motivated to develop drugs and treatments, resulting in more advanced treatment options. Furthermore, given the critical need for treatments in the late stages of the illness, medical professionals and patients are more willing to accept novel therapy, regardless of cost. This dynamic supports macular degeneration treatment market growth and advancement for these treatments.

Breakup by Route of Administration:

  • Intravenous Route
  • Intravitreal Route

Intravitreal route holds the maximum share in the market

The intravitreal route is a critical driver in the market. This strategy considers designated treatment, lessening fundamental secondary effects, and working on quiet results. The rising prevalence of age-related macular degeneration and diabetic retinopathy enhances the interest in intravitreal routes. Headways in drug plans and conveyance procedures further improve the allure of this route. Furthermore, the intravitreal administration's demonstrated adequacy in clinical trials upholds its adoption by ophthalmologists, thus fueling the macular degeneration treatment demand.

Breakup by End User:

  • Hospitals
  • Ambulatory Surgical Center
  • Others

Hospitals hold the maximum share in the market

Hospitals play an important role in providing a boost to the market. Their excellent diagnostic capabilities and specialized care facilities appeal to patients seeking complete eye care. They also provide a platform for the implementation of cutting-edge technologies and therapies, which improve patient outcomes. Collaboration between hospitals and pharmaceutical companies speeds up the development of new medications and treatment methods. Furthermore, the emphasis on quality care and patient management in hospitals increases demand for effective macular degeneration therapies, which contributes significantly to market expansion.

Breakup by Region:

  • North America
    • United States
    • Canada
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Others
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa

North America leads the market, accounting for the largest macular degeneration treatment market share

The market research report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America represents the largest regional market for macular degeneration treatment.

North America dominated the market with the highest revenue share and the presence of a large number of major macular degeneration treatment companies. This dominance can be attributed to the rising prevalence of AMD. According to the American Academy of Ophthalmology, around 15 million individuals in North American live with AMD. There is also a high prevalence of macular degeneration in the region, which is expected to rise in the coming years. Furthermore, the growing geriatric population and disease burden are also propelling the market. The favorable government initiatives to support the affordability of costly anti-VEGF products are expected to contribute to the market growth.

COMPETITIVE LANDSCAPE:

The market research report has provided a comprehensive analysis of the competitive landscape. Detailed profiles of all major companies have also been provided. Some of the key players in the market include:

  • Alcon Inc.
  • Apellis Pharmaceuticals, Inc.
  • Astellas Pharma US, Inc.
  • Bausch + Lomb
  • Bayer Consumer Care AG
  • F. Hoffmann-La Roche Ltd
  • Novartis Pharmaceuticals Corporation
  • Ocular Therapeutix, Inc.
  • Regeneron Pharmaceuticals Inc.
  • Regenxbio Inc.
  • Samsung Bioepis

Frequent approvals and launches of novel medications by key players are resulting in macular degeneration treatment market recent developments. Increased investments in R&D are pivotal for the development of effective treatments. Notably, companies are investing in genetic medicines and the development of novel drugs such as anti-VEGF (Vascular Endothelial Growth Factor) therapies. For example, in October 2021, Roche announced that the Food and Drug Administration (FDA) had approved Susvimo (100 mg/mL ranibizumab injection) to treat wet, or neovascular, age-related macular degeneration (AMD), a disease that can cause rapid and severe vision loss. Also, there's a notable trend of mergers, acquisitions, and partnerships among key players aiming to consolidate market presence and enhance their product portfolios. Companies are also focusing on expanding their reach in high-growth regions such as Asia-Pacific, where the increasing geriatric population and government initiatives to improve healthcare accessibility is favorably impacting the market. Apart from this, some of the macular degeneration treatment market recent opportunities include leveraging state-of-the-art technologies for enhancing patient outcome by various major players and the introduction of AI-powered imaging and analytics for improving the accuracy of diagnoses and enabling personalized treatment plans.

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Macular Degeneration Treatment Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Type

  • 6.1 Dry Age-related Macular Degeneration
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Wet Age-related Macular Degeneration
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast

7 Market Breakup by Stage of Disease

  • 7.1 Early Stage
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Intermediate Stage
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Late Stage
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast

8 Market Breakup by Route of Administration

  • 8.1 Intravenous Route
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Intravitreal Route
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast

9 Market Breakup by End User

  • 9.1 Hospitals
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Ambulatory Surgical Center
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast
  • 9.3 Others
    • 9.3.1 Market Trends
    • 9.3.2 Market Forecast

10 Market Breakup by Region

  • 10.1 North America
    • 10.1.1 United States
      • 10.1.1.1 Market Trends
      • 10.1.1.2 Market Forecast
    • 10.1.2 Canada
      • 10.1.2.1 Market Trends
      • 10.1.2.2 Market Forecast
  • 10.2 Asia-Pacific
    • 10.2.1 China
      • 10.2.1.1 Market Trends
      • 10.2.1.2 Market Forecast
    • 10.2.2 Japan
      • 10.2.2.1 Market Trends
      • 10.2.2.2 Market Forecast
    • 10.2.3 India
      • 10.2.3.1 Market Trends
      • 10.2.3.2 Market Forecast
    • 10.2.4 South Korea
      • 10.2.4.1 Market Trends
      • 10.2.4.2 Market Forecast
    • 10.2.5 Australia
      • 10.2.5.1 Market Trends
      • 10.2.5.2 Market Forecast
    • 10.2.6 Indonesia
      • 10.2.6.1 Market Trends
      • 10.2.6.2 Market Forecast
    • 10.2.7 Others
      • 10.2.7.1 Market Trends
      • 10.2.7.2 Market Forecast
  • 10.3 Europe
    • 10.3.1 Germany
      • 10.3.1.1 Market Trends
      • 10.3.1.2 Market Forecast
    • 10.3.2 France
      • 10.3.2.1 Market Trends
      • 10.3.2.2 Market Forecast
    • 10.3.3 United Kingdom
      • 10.3.3.1 Market Trends
      • 10.3.3.2 Market Forecast
    • 10.3.4 Italy
      • 10.3.4.1 Market Trends
      • 10.3.4.2 Market Forecast
    • 10.3.5 Spain
      • 10.3.5.1 Market Trends
      • 10.3.5.2 Market Forecast
    • 10.3.6 Russia
      • 10.3.6.1 Market Trends
      • 10.3.6.2 Market Forecast
    • 10.3.7 Others
      • 10.3.7.1 Market Trends
      • 10.3.7.2 Market Forecast
  • 10.4 Latin America
    • 10.4.1 Brazil
      • 10.4.1.1 Market Trends
      • 10.4.1.2 Market Forecast
    • 10.4.2 Mexico
      • 10.4.2.1 Market Trends
      • 10.4.2.2 Market Forecast
    • 10.4.3 Others
      • 10.4.3.1 Market Trends
      • 10.4.3.2 Market Forecast
  • 10.5 Middle East and Africa
    • 10.5.1 Market Trends
    • 10.5.2 Market Breakup by Country
    • 10.5.3 Market Forecast

11 SWOT Analysis

  • 11.1 Overview
  • 11.2 Strengths
  • 11.3 Weaknesses
  • 11.4 Opportunities
  • 11.5 Threats

12 Value Chain Analysis

13 Porters Five Forces Analysis

  • 13.1 Overview
  • 13.2 Bargaining Power of Buyers
  • 13.3 Bargaining Power of Suppliers
  • 13.4 Degree of Competition
  • 13.5 Threat of New Entrants
  • 13.6 Threat of Substitutes

14 Price Analysis

15 Competitive Landscape

  • 15.1 Market Structure
  • 15.2 Key Players
  • 15.3 Profiles of Key Players
    • 15.3.1 Alcon Inc.
      • 15.3.1.1 Company Overview
      • 15.3.1.2 Product Portfolio
      • 15.3.1.3 Financials
      • 15.3.1.4 SWOT Analysis
    • 15.3.2 Apellis Pharmaceuticals, Inc.
      • 15.3.2.1 Company Overview
      • 15.3.2.2 Product Portfolio
      • 15.3.2.3 Financials
      • 15.3.2.4 SWOT Analysis
    • 15.3.3 Astellas Pharma US, Inc.
      • 15.3.3.1 Company Overview
      • 15.3.3.2 Product Portfolio
      • 15.3.3.3 Financials
      • 15.3.3.4 SWOT Analysis
    • 15.3.4 Bausch + Lomb
      • 15.3.4.1 Company Overview
      • 15.3.4.2 Product Portfolio
      • 15.3.4.3 Financials
      • 15.3.4.4 SWOT Analysis
    • 15.3.5 Bayer Consumer Care AG
      • 15.3.5.1 Company Overview
      • 15.3.5.2 Product Portfolio
      • 15.3.5.3 Financials
      • 15.3.5.4 SWOT Analysis
    • 15.3.6 F. Hoffmann-La Roche Ltd
      • 15.3.6.1 Company Overview
      • 15.3.6.2 Product Portfolio
      • 15.3.6.3 Financials
    • 15.3.7 Novartis Pharmaceuticals Corporation
      • 15.3.7.1 Company Overview
      • 15.3.7.2 Product Portfolio
      • 15.3.7.3 Financials
      • 15.3.7.4 SWOT Analysis
    • 15.3.8 Ocular Therapeutix, Inc.
      • 15.3.8.1 Company Overview
      • 15.3.8.2 Product Portfolio
      • 15.3.8.3 Financials
      • 15.3.8.4 SWOT Analysis
    • 15.3.9 Regeneron Pharmaceuticals Inc.
      • 15.3.9.1 Company Overview
      • 15.3.9.2 Product Portfolio
      • 15.3.9.3 Financials
      • 15.3.9.4 SWOT Analysis
    • 15.3.10 Regenxbio Inc.
      • 15.3.10.1 Company Overview
      • 15.3.10.2 Product Portfolio
      • 15.3.10.3 Financials
      • 15.3.10.4 SWOT Analysis
    • 15.3.11 Samsung Bioepis
      • 15.3.11.1 Company Overview
      • 15.3.11.2 Product Portfolio
      • 15.3.11.3 Financials
      • 15.3.11.4 SWOT Analysis

List of Figures

  • Figure 1: Global: Macular Degeneration Treatment Market: Major Drivers and Challenges
  • Figure 2: Global: Macular Degeneration Treatment Market: Sales Value (in Billion USD), 2020-2025
  • Figure 3: Global: Macular Degeneration Treatment Market Forecast: Sales Value (in Billion USD), 2026-2034
  • Figure 4: Global: Macular Degeneration Treatment Market: Breakup by Type (in %), 2025
  • Figure 5: Global: Macular Degeneration Treatment Market: Breakup by Stage of Disease (in %), 2025
  • Figure 6: Global: Macular Degeneration Treatment Market: Breakup by Route of Administration (in %), 2025
  • Figure 7: Global: Macular Degeneration Treatment Market: Breakup by End User (in %), 2025
  • Figure 8: Global: Macular Degeneration Treatment Market: Breakup by Region (in %), 2025
  • Figure 9: Global: Macular Degeneration Treatment (Dry Age-related Macular Degeneration) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 10: Global: Macular Degeneration Treatment (Dry Age-related Macular Degeneration) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 11: Global: Macular Degeneration Treatment (Wet Age-related Macular Degeneration) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 12: Global: Macular Degeneration Treatment (Wet Age-related Macular Degeneration) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 13: Global: Macular Degeneration Treatment (Early Stage) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 14: Global: Macular Degeneration Treatment (Early Stage) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 15: Global: Macular Degeneration Treatment (Intermediate Stage) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 16: Global: Macular Degeneration Treatment (Intermediate Stage) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 17: Global: Macular Degeneration Treatment (Late Stage) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 18: Global: Macular Degeneration Treatment (Late Stage) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 19: Global: Macular Degeneration Treatment (Intravenous Route) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 20: Global: Macular Degeneration Treatment (Intravenous Route) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 21: Global: Macular Degeneration Treatment (Intravitreal Route) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 22: Global: Macular Degeneration Treatment (Intravitreal Route) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 23: Global: Macular Degeneration Treatment (Hospitals) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 24: Global: Macular Degeneration Treatment (Hospitals) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 25: Global: Macular Degeneration Treatment (Ambulatory Surgical Center) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 26: Global: Macular Degeneration Treatment (Ambulatory Surgical Center) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 27: Global: Macular Degeneration Treatment (Other End Users) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 28: Global: Macular Degeneration Treatment (Other End Users) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 29: North America: Macular Degeneration Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 30: North America: Macular Degeneration Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 31: United States: Macular Degeneration Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 32: United States: Macular Degeneration Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 33: Canada: Macular Degeneration Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 34: Canada: Macular Degeneration Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 35: Asia-Pacific: Macular Degeneration Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 36: Asia-Pacific: Macular Degeneration Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 37: China: Macular Degeneration Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 38: China: Macular Degeneration Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 39: Japan: Macular Degeneration Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 40: Japan: Macular Degeneration Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 41: India: Macular Degeneration Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 42: India: Macular Degeneration Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 43: South Korea: Macular Degeneration Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 44: South Korea: Macular Degeneration Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 45: Australia: Macular Degeneration Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 46: Australia: Macular Degeneration Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 47: Indonesia: Macular Degeneration Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 48: Indonesia: Macular Degeneration Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 49: Others: Macular Degeneration Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 50: Others: Macular Degeneration Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 51: Europe: Macular Degeneration Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 52: Europe: Macular Degeneration Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 53: Germany: Macular Degeneration Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 54: Germany: Macular Degeneration Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 55: France: Macular Degeneration Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 56: France: Macular Degeneration Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 57: United Kingdom: Macular Degeneration Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 58: United Kingdom: Macular Degeneration Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 59: Italy: Macular Degeneration Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 60: Italy: Macular Degeneration Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 61: Spain: Macular Degeneration Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 62: Spain: Macular Degeneration Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 63: Russia: Macular Degeneration Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 64: Russia: Macular Degeneration Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 65: Others: Macular Degeneration Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 66: Others: Macular Degeneration Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 67: Latin America: Macular Degeneration Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 68: Latin America: Macular Degeneration Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 69: Brazil: Macular Degeneration Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 70: Brazil: Macular Degeneration Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 71: Mexico: Macular Degeneration Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 72: Mexico: Macular Degeneration Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 73: Others: Macular Degeneration Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 74: Others: Macular Degeneration Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 75: Middle East and Africa: Macular Degeneration Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 76: Middle East and Africa: Macular Degeneration Treatment Market: Breakup by Country (in %), 2025
  • Figure 77: Middle East and Africa: Macular Degeneration Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 78: Global: Macular Degeneration Treatment Industry: SWOT Analysis
  • Figure 79: Global: Macular Degeneration Treatment Industry: Value Chain Analysis
  • Figure 80: Global: Macular Degeneration Treatment Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Macular Degeneration Treatment Market: Key Industry Highlights, 2025 and 2034
  • Table 2: Global: Macular Degeneration Treatment Market Forecast: Breakup by Type (in Million USD), 2026-2034
  • Table 3: Global: Macular Degeneration Treatment Market Forecast: Breakup by Stage of Disease (in Million USD), 2026-2034
  • Table 4: Global: Macular Degeneration Treatment Market Forecast: Breakup by Route of Administration (in Million USD), 2026-2034
  • Table 5: Global: Macular Degeneration Treatment Market Forecast: Breakup by End User (in Million USD), 2026-2034
  • Table 6: Global: Macular Degeneration Treatment Market Forecast: Breakup by Region (in Million USD), 2026-2034
  • Table 7: Global: Macular Degeneration Treatment Market: Competitive Structure
  • Table 8: Global: Macular Degeneration Treatment Market: Key Players